KIM-1 as a potential serological/urinological tumor-associated marker of renal cell carcinoma and chemotherapy nephrotoxicity-Reference-Cited by-同舟云学术

KIM-1 as a potential serological/urinological tumor-associated marker of renal cell carcinoma and chemotherapy nephrotoxicity

Published:2019-10-09 Issue:3 Volume:15 Page:132-142
ISSN:1996-1812
Container-title:Cancer Urology
language:
Short-container-title:Onkourologiâ

Author:

Solokhina M. P.¹^ORCID,Sergeeva N. S.²^ORCID,Marshutina N. V.¹^ORCID,Alentov I. I.¹^ORCID,Kanukoev K. Yu.¹,Nyushko K. M.¹^ORCID,Alekseev B. Ya.¹^ORCID,Kaprin A. D.¹^ORCID

Affiliation:

1. National Medical Research Radiological Center, Ministry of Health of Russia

2. National Medical Research Radiological Center, Ministry of Health of Russia; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia

Abstract

The last decades are characterized by an active search for highly sensitive and specific urinological and serological tumor-associated markers of renal cell carcinoma. This review analyses the results of studies of traditional serological tumor-associated markers and a potential new tumor-associated marker of renal cell carcinoma: kidney injury molecule-1, or KIM-1. The structure, sources and functions of KIM-1 in normal conditions and in damaged renal tubules, its potential role in carcinogenesis are described. The experience of using KIM-1 for specifying diagnosis of the most common histological types of renal cell carcinoma is analyzed. Data on KIM-1 expression in malignant tumors in other locations and non-oncological kidney disorders are presented. The role of KIM-1 in early diagnosis of nephrotoxic effect of antitumor drugs is described. The accumulated data is promising in regards to using KIM-1 in clinical oncology as a urinological and serological marker of renal cell carcinoma and chemotherapy nephrotoxicity.

Publisher

Publishing House ABV Press

Subject

Urology,Nephrology,Radiology Nuclear Medicine and imaging,Oncology,Surgery

Reference79 articles.

1. State of oncological care in Russia in 2017. Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMIRTS radiologii” Minzdrava Rossii, 2018. 236 p. (In Russ.).

2. Grankvist K., Ljungberg B., Rasmuson T. Evaluation of five glycoprotein tumour markers (CEA, CA-50, CA-19-9, CA-125, CA-15-3) for the prognosis of renal-cell carcinoma. Int J Cancer 1997;74(2):233–6. DOI: 10.1002/(SICI)10970215(19970422)74:2<233::AIDIJC17>3.0.CO;2-E.

3. Jacobsen J., Rasmuson T., Grankvist K., Ljungberg B. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 2000;163(1):343–7. DOI: 10.1097/00005392-20000100000092.

4. Banyra O.B., Stroy A.A., Shulyak A.V. Tumor markers in kidney cancer diagnosing. Eksperimental’naya i klinicheskaya urologiya = Experimental and Clinical Urology 2011;4:72–8. (In Russ.).

5. Hotakainen K., Ljungberg B., Paju A. et al. The free β-subunit of human chorionic gonadotropin as a prognostic factor in renal cell carcinoma. Br J Cancer 2002;86(2):185–9. DOI: 10.1038/sj.bjc.6600050.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of biomarkers of acute kidney injury in predicting functional outcomes of surgical treatment of patients with localized kidney cancer;Research and Practical Medicine Journal;2021-09-26

2. Features of Acute Coronary Syndrome in Combination with Oncological Diseases in Elderly and Senile Patients;The Russian Archives of Internal Medicine;2021-03-30

3. Clinical implication of kidney injury molecule (KIM-1) in blood plasma of renal-cell cancer patients;Cancer Urology;2021-02-10

4. KIM-1 (kidney injury molecule 1) in the urine of renal cell carcinoma patients;Cancer Urology;2020-11-19